2 results
Approved WMOCompleted
Part A1(KIN-2787 Monotherapy Escalation):Determine safety and tolerability of PO administration of Kin-2787 including DLT in participants with BRAFmutation-positive advanced or metastatic solid tumors or melanoma harboring NRAS-mutation. Identify…
Approved WMORecruiting
Part 1 (phase 1b)Primary:• To observe the safety and tolerability of bemarituzumabSecondary:• To evaluate preliminary antitumor activity• Characterize the pharmacokinetics (PK) of bemarituzumab Part 2 (phase 2)Primary:• To evaluate preliminary…